BioSpace News Archive

An open-label, multi-cohort Phase II trial, led by investigators at The University of Texas MD Anderson Cancer Center, reports that treatment with the drug tagraxofusp resulted in high response rates in patients with blastic plasmacytoid dendritic cell neoplasm, a rare but highly aggressive – and often fatal bone marrow and blood disorder – for which there are no existing approved therapies.

The employees were terminated over allegations of industrial espionage on behalf of the Chinese government. MD Anderson ought to quell concerns of racial profiling following the firings.

The U.S. Department of Justice (DOJ) is reviewing a government patent for HIV, according to a retired Centers for Disease Control and Prevention (CDC) scientist.

Two large companies with extensive involvement in the biopharma industry have announced major construction projects.

Researchers with the University of California San Francisco (UCSF) developed a “neural decoder” that translates brain activity to synthesize audible speech. They published their research in the journal Nature.

The funding will be used to expand the production capacity of key components of the adjuvant system used in several of GSK’s vaccines, including shingles vaccine, Shingrix.

There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.

On Wednesday, Kite and Gilead announced the 20-acre facility in Fredericksburg that is expected to employ more than 400 people when it becomes operational.

Eli Lilly and Company announced that as it withdraws Lartruvo (olaratumab) from the market for treatment of advanced soft tissue sarcoma (STS), it is establishing an Access Program for patients currently receiving the drug who may wish to continue.

Companies strengthen leadership teams with C-suite and boards of directors appointments, with new hires at Sandoz, Mission Bio, SkinBio, Epic Sciences, and more.